Solid Biosciences is a life science company focused solely on finding meaningful therapies for Duchenne muscular dystrophy (DMD). Founded by individuals touched by the disease, Solid is a center of excellence for DMD, bringing together experts in science, technology and care to drive forward a portfolio of candidates that have life-changing potential. Solid is advancing programs across four scientific platforms: Corrective Therapies, Disease-Modifying Therapies, Disease Understanding and Assistive Devices. The company’s lead candidate, SGT-001, is an adeno-associated viral (AAV) vector-mediated gene therapy, which is currently under investigation in a clinical trial called IGNITE DMD.